• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Mineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/22/25 4:14:54 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email
    mlys-20250522
    false000193341400019334142025-05-222025-05-22

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934
    Date of report (Date of earliest event reported): May 22, 2025
    MINERALYS THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)
    Delaware
    001-41614
    84-1966887
    (State or other jurisdiction of incorporation
    or organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    150 N. Radnor Chester Road, Suite F200
    Radnor, Pennsylvania 19087
    (Address of principal executive offices) (Zip Code)
    (888) 378-6240
    (Registrant’s telephone number, include area code)
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
    MLYS
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.07. Submission of Matters to a Vote of Security Holders.
    On May 22, 2025, Mineralys Therapeutics, Inc. (the Company) held its 2025 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown:
    Proposal 1 – To elect two directors to serve as Class II directors for a three-year term to expire at the 2028 annual meeting of stockholders.
    NameForWithholdBroker Non-Votes
    Glenn P. Sblendorio45,445,5667,503,7586,363,413
    Derek DiRocco, Ph.D.45,305,8897,643,4356,363,413
    Proposal 2 – To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
    ForAgainstAbstainBroker Non-Votes
    59,115,4395,916191,3820
    Both Proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company’s common stock.
    Each Proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 9, 2025.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Dated: May 22, 2025MINERALYS THERAPEUTICS, INC.
    By:/s/ Adam Levy
    Name:Adam Levy
    Title:Chief Financial Officer and Secretary

    Get the next $MLYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    6/11/2025$15.00Hold
    Jefferies
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    More analyst ratings

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      4/25/25 7:01:59 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      3/17/25 9:05:47 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      3/17/25 9:04:15 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rodman David Malcom exercised 6,348 shares at a strike of $1.08 and sold $165,931 worth of shares (11,366 units at $14.60), decreasing direct ownership by 5% to 101,651 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      6/16/25 4:03:20 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rodman David Malcom sold $173,774 worth of shares (11,366 units at $15.29), decreasing direct ownership by 10% to 106,669 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      5/15/25 7:01:41 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08, increasing direct ownership by 6% to 118,035 units (SEC Form 4)

      4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

      5/13/25 8:57:09 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Mineralys Therapeutics with a new price target

      Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

      6/11/25 7:54:20 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

      7/10/24 7:50:59 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Mineralys Therapeutics with a new price target

      Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

      4/2/24 7:34:24 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLYS
    SEC Filings

    See more
    • Mineralys Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

      6/17/25 7:07:35 AM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Mineralys Therapeutics Inc.

      144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

      6/13/25 4:23:01 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

      5/22/25 4:14:54 PM ET
      $MLYS
      Biotechnology: Pharmaceutical Preparations
      Health Care